Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Braun, J.
Right arrow Articles by Hörl, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braun, J.
Right arrow Articles by Hörl, W. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1996) 11: 492-497
© 1996 European Renal Association-European Dialysis and Transplant Association


research-article

Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients?

J. Braun1,, M. Hammerschmidt1, M. Schreiber1, R. Heidler1 and W. H. Hörl2

1Haemodialysis Unit Nürnberg Nürnberg, Germany 2Department of Nephrology, University of Vienna Vienna, Austria

Correspondence and offprint requests to: Correspondence and offprint requests to: Priv.-Doz. Dr J. Braun, KfH Dialysezentrum Nürnberg, Virnsbergerstr. 43, D-90431 Nürnberg, Germany

BACKGROUND.: Zinc protoporphyrin (ZPP), a metabolic intermediate generated in the red blood cell by incorporation of zinc instead of iron, has been suggested to be a sensitive and specific parameter of absolute iron deficiency in haemodialysis (HD) patients.

METHODS.: We studied 62 HD patients, 29–86 years old, with ZPP levels >50 µmol/mol haeme (normal value of ZPP <40 µmol/mol haeme) assessing the value of ZPP as a marker of functional iron deficiency at different cut-off points of ZPP. None of the patients had apparent inflammatory disease, infectious disease, or malignancy. ZPP, haemoglobin, iron and ferritin levels were determined before, and after a 24-week period of once-weekly i.v. administration of 40 mg iron, to determine whether ZPP levels return to normal during adequate iron supplementation (960 mg iron/patient).

RESULTS.: There was no significant change in ZPP levels after iron supplementation in patients with a ZPP >50 µmol/mol haeme (96.7±49.8 versus 88.4±43.5 µmol/mol haeme before and after iron administration respectively, P=n.s.). However, in patients with a ZPP >90 µmol/mol haeme, there was a significant reduction in ZPP levels (141.2±54.5 versus 108.0±48.8 µmol/mol haeme, P<0.001). Serum ferritin increased significantly in both groups. There was no correlation between ZPP and serum ferritin at any time during the study. There was also no correlation between serum aluminium levels and ZPP and no significant difference in changes in ZPP in patients receiving desferrioxamine therapy compared to those not receiving desferrioxamine therapy. We did find a significant correlation between moderately elevated total blood lead concentrations and ZPP levels at the end of the study. The ZPP levels were not significantly different in the range from 50–110 µmol/mol haeme before and after i.v. iron supplementation in the responders (10% increase of haemoglobin or 20% decrease of the recombinant human erythropoietin dose) compared with the non-responders.

CONCLUSIONS.: Our data indicate that ZPP cannot be used to predict the erythropoietic response to iron supplementation. However, ZPP levels may be an indicator of functional iron deficiency due to blockade of the reticuloendothelial iron release in haemodialysis patients.

Keywords: anaemia; iron deficiency; haemodialysis; zinc protoporphyrin; lead


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
A. BESARAB, N. AMIN, M. AHSAN, S. E. VOGEL, G. ZAZUWA, S. FRINAK, J. J. ZAZRA, J. V. ANANDAN, and A. GUPTA
Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients
J. Am. Soc. Nephrol., March 1, 2000; 11(3): 530 - 538.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. F. Labbe, H. J. Vreman, and D. K. Stevenson
Zinc Protoporphyrin: A Metabolite with a Mission
Clin. Chem., December 1, 1999; 45(12): 2060 - 2072.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.